France Renal Failure Treatment Market Size, Share, By Treatment (Dialysis, Kidney Transplantation, Drug Therapy, and Others), By End Use (Specialty Clinics and Hospitals), and France Renal Failure Treatment Market Insights, Industry Trend, Forecasts to 2035

France Renal Failure Treatment Market Size Insights Forecasts to 2035

• France Renal Failure Treatment Market Size 2024: USD 4,455.14 Mn
• France Renal Failure Treatment Market Size 2035:  USD 8,902.14 Mn
• France Renal Failure Treatment Market CAGR 2024: 6.5%
• France Renal Failure Treatment Market Segments: Treatment and end use

The France Renal Failure Treatment Market Size is the market for medical therapies, devices, and services utilized to manage and treat acute and chronic kidney failure in patients across hospitals, dialysis centers, and home care settings in France. The market also comprises dialysis treatments, renal replacement therapies, medications, and supportive care aimed at patient outcomes and quality of life improvement. The main factors leading to the expansion of the market are the increasing prevalence of chronic kidney disease (CKD) and the associated comorbidities such as diabetes and hypertension, the rising demand for dialysis and renal replacement therapies, the technological innovations in hemodialysis and peritoneal dialysis equipment, and the awareness of early diagnosis and management of renal diseases among healthcare providers and patients.

Market Dynamics of the France Renal Failure Treatment Market:

The France Renal Failure Treatment Market Size is primarily influenced by the increasing chronic kidney disease incidences that are leading to numerous associated conditions like diabetes and hypertension. The market expansion is being fuelled by the demand for dialysis and renal replacement therapies, technological innovations in treatment appliances, and better healthcare access. Furthermore, patient and healthcare provider awareness of early diagnosis and disease management is also leading to increased treatment uptake.

The market for treatment of renal failure in France is restrained by factors such as the expensive dialysis and long-term renal care, a shortage of available donor kidneys for transplantation, and the physical and emotional suffering that lifelong treatment causes to patients. Moreover, staff shortages, regions with inadequate facilities, and stringent regulations may restrict the opening of new dialysis centers and slow the pace of the adoption of advanced renal therapies.

The renal failure treatment market in France looks vibrant in the coming years. The major opportunities are mainly due to the increasing preference for home and portable dialysis solutions, the incorporation of digital health, and personalized renal care. Remote patient monitoring, AI-supported treatment planning, and regenerative medicine research are anticipated to bring better clinical outcomes, elevate patient quality of life, and help more efficient long-term management of kidney disease throughout France.

Market Segmentation

The France Renal Failure Treatment Market Size, share is classified into treatment and end use.

By Treatment:

The France Renal Failure Treatment Market Size is divided by treatment into dialysis, kidney transplantation, drug therapy, and others. Among these, the dialysis segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The growth of the dialysis segment is due to the high prevalence of chronic kidney disease and end-stage renal disease, limited availability of donor kidneys, increasing elderly population, and expanding access to in-center and home-based dialysis services across France.

By End Use:

The France Renal Failure Treatment Market Size is divided by end use into specialty clinics and hospitals. Among these, the hospitals segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The hospitals segment dominates because of the availability of advanced dialysis infrastructure, multidisciplinary nephrology care, skilled healthcare professionals, and the ability to manage complex and emergency renal failure cases under one setting across France.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the France Renal Failure Treatment Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in France Renal Failure Treatment Market:

• Fresenius Medical Care
• Baxter International
• DaVita Inc.
• B. Braun Melsungen AG
• Nipro Corporation
• Medtronic plc
• Sanofi
• AbbVie Inc.
• Astellas Pharma
• Vifor Pharma
• Others

Recent Developments in France Renal Failure Treatment Market:

• In January 2025, Novo Nordisk’s Ozempic (semaglutide) received FDA approval to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on Phase IIIb trial results showing a 24% risk reduction.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the France Renal Failure Treatment Market Size based on the below-mentioned segments:

France Renal Failure Treatment Market, By Treatment

• Dialysis
• Kidney Transplantation
• Drug Therapy
• Others

France Renal Failure Treatment Market, By End Use

• Specialty Clinics
• Hospitals